Literature DB >> 36124195

What can we learn from negative results in clinical trials for proliferative vitreoretinopathy?

Peter Wiedemann1.   

Abstract

Entities:  

Year:  2022        PMID： 36124195      PMCID： PMC9453418          DOI： 10.18240/ijo.2022.09.01

Source DB:  PubMed          Journal:  Int J Ophthalmol        ISSN： 2222-3959            Impact factor:   1.645


× No keyword cloud information.
  3 in total

1.  Slow-Release Dexamethasone in Proliferative Vitreoretinopathy: A Prospective, Randomized Controlled Clinical Trial.

Authors:  Philip J Banerjee; Ana Quartilho; Catey Bunce; Wen Xing; Tapiwa M Zvobgo; Nicola Harris; David G Charteris
Journal:  Ophthalmology       Date:  2017-02-23       Impact factor: 12.079

2.  Intravitreal 5-Fluorouracil and Heparin to Prevent Proliferative Vitreoretinopathy: Results from a Randomized Clinical Trial.

Authors:  Friederike Schaub; Petra Schiller; Robert Hoerster; Daria Kraus; Frank G Holz; Rainer Guthoff; Hansjürgen Agostini; Martin S Spitzer; Peter Wiedemann; Albrecht Lommatzsch; Karl T Boden; Spyridon Dimopoulos; Sebastian Bemme; Svenja Tamm; Mathias Maier; Johann Roider; Philip Enders; Lebriz Altay; Sascha Fauser; Bernd Kirchhof
Journal:  Ophthalmology       Date:  2022-06-07       Impact factor: 14.277

3.  Adjunctive daunorubicin in the treatment of proliferative vitreoretinopathy: results of a multicenter clinical trial. Daunomycin Study Group.

Authors:  P Wiedemann; R D Hilgers; P Bauer; K Heimann
Journal:  Am J Ophthalmol       Date:  1998-10       Impact factor: 5.258
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.